In this study, we hypothesized that cilostazol can be associated with the expression of PCSK9 and lipid metabolism through AMPKα/PPARγ signaling pathway, the effects of cilostazol treatment on PCSK9 will be different between obesity and non-obesity, and lipid metabolism-relevant miRNAs will partly contribute to the diverse effects. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.